Ziyuan Gao Selected Research

osimertinib

1/2022

Salvage therapy of osimertinib plus anlotinib in advanced lung adenocarcinoma with leptomeningeal metastasis: A case report.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ziyuan Gao Research Topics

Disease

4	Neoplasms (Cancer) 02/2023 - 01/2022
3	Neoplasm Metastasis (Metastasis) 02/2023 - 01/2022
2	Carcinogenesis 02/2023 - 01/2022
2	Adenocarcinoma of Lung 05/2022 - 01/2022
1	Alzheimer Disease (Alzheimer's Disease) 01/2022
1	Lung Neoplasms (Lung Cancer) 01/2022
1	COVID-19 01/2022

Drug/Important Bio-Agent (IBA)

3	Glycoproteins (Glycoprotein)IBA 02/2023 - 01/2022
1	MicroRNAs (MicroRNA)IBA 01/2023
1	Antiviral Agents (Antivirals)IBA 01/2022
1	Immunologic Factors (Immunomodulators)IBA 01/2022
1	Membrane Glycoproteins (Membrane Glycoprotein)IBA 01/2022
1	tyrosine receptor (receptor, tyrosine)IBA 01/2022
1	anlotinibIBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	Polysaccharides (Glycans)IBA 01/2022
1	Proteins (Proteins, Gene)FDA Link 01/2022
1	Sialic AcidsIBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Amyloid beta-PeptidesIBA 01/2022
1	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2022
1	osimertinibIBA 01/2022
1	Vaccine AdjuvantsIBA 01/2022

Therapy/Procedure

1	Salvage Therapy 01/2022